Table 1 Individual patient clinical information, pMGMT status, and PDT drug responses to clinical drugs TMZ and CCNU.
ID | Age | Sex | Histologic diagnosis | TMZ Treated | pMGMT (%) | TMZ (%)a | CCNU (%)b |
|---|---|---|---|---|---|---|---|
2509-HS | 43 | M | Astrocytoma, IV, IDH1 mut (R) | Yes | 12.0c | 121 | - |
2745-HS | 51 | M | Oligodendroglioma, III, IDH1 mut (R) | Yes | 31.2c | 138 | 98 |
2766-HS | 41 | M | Oligodendroglioma, III, IDH1 mut | No | 39.5c | 106 | 70 |
3056-HS | 35 | F | Astrocytoma, IV, IDH1 mut (R) | Yes | 30.7c | 124 | 61 |
3199-HS | 27 | F | Giant cell glioblastoma, IV, IDH1/2 WT | No | 49.0c | 93 | 44 |
3833-HS | 21 | M | Pediatric High-Grade Glioma, IV, IDH1/2 WT (R) | No | 1.7 | 99 | 101 |
3917-HS | 43 | F | Oligodendroglioma, III (R) | Yes | 19.0c | 114 | 31 |
4089-HS | 45 | M | Glioblastoma, IV, IDH1/2 WT (R) | Yes | 38.2c | 112 | 57 |
4240-HS | 37 | M | Gliosarcoma, IV, IDH1/2 WT (R) | Yes | - | 130 | 39 |
4358-HS | 67 | M | Glioblastoma, IV, IDH1/2 WT | No | 1.5 | 81 | 82 |
4468-HS | 64 | M | Glioblastoma, IV, IDH1/2 WT | No | 1.5 | 92 | 36 |
4671-HS | 55 | F | Glioblastoma, IV, IDH1/2 WT | No | 7.0 | 62 | 29 |
5256-HS | 31 | F | Astrocytoma, IV, IDH1 mut (R) | Yes | 47.3c | 92 | 74 |
0810-HS | 66 | M | Glioblastoma, IV, IDH1/2 WT | No | 2.0 | 91 | 83 |
1779-HS | 52 | M | Glioblastoma, IV, IDH1/2 WT | No | 2.25 | 106 | 92 |
1869-HS | 74 | M | Glioblastoma, IV, IDH1/2 WT | No | 29.7c | - | - |
1864-HS | 65 | M | Glioblastoma, IV, IDH1/2 WT | No | 2.75 | 106 | 101 |
10308-HS | 39 | M | Gliosarcoma, IV, IDH1/2 WT (R) | Yes | 1.5 | 104 | 90 |
0911-HS | 58 | F | Glioblastoma, IV, IDH1/2 WT | No | 33c | 84 | 113 |
27691-HS | 70 | F | Glioblastoma, IV, IDH1/2 WT | No | 2.0 | 102 | 84 |
28372-HS | 32 | F | Astrocytoma, IV, IDH1/2 mut (R) | Yes | 3.0 | 106 | 96 |
29259-HS | 67 | F | Glioblastoma, IV, IDH1/2 WT | No | - | 101 | 94 |
5371-HS | 42 | F | Astrocytoma, III, IDH1 mut | No | 21.2c | 99 | 102 |
